A
Alcista
Alcista · 25%TEVA
$17.88
Precio del escenario
$40.850
-0.453 (-1.11%)Al cierre
Loading chart…
- Máximo
- 41.590
- Apertura
- 41.480
- Precio medio ponderado por volumen
- 41.08
- Volumen
- 4.22M
- Capitalización
- 18.42B
- Mínimo
- 40.800
- Importe
- 173.54M
- EV/EBITDA, TTM
- 36.48
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Análisis de IA of Teva Pharmaceutical Industries Limited.. (TEVA)
ComprarTeva Pharmaceutical is a good buy right now due to its recent FDA approval of Weltruza, which has the potential to significantly increase market share in the mental health sector. The current price is $41.50, and analysts have set a price target range between $50 and $55, indicating a potential upside of 20% to 32%. Additionally, the stock has shown strong momentum with a 1-year change of +113.70% and a 20-day change of +6.46%. However, the main risk is the recent insider selling, which has increased by 764.83%, suggesting potential concerns among insiders about the company's future performance.
Recomendaciones de analistas (26)
-12.58% Potencial de caída
Mantener
4 Comprar
17 Mantener
5 Vender
Actual: 40.85
Mínimo
29.00
Promedio
35.71
Máximo
40.00
JPMorgan
Sobreponderar
$50
2026-10-11
JPMorgan
2026-10-11
Precio objetivo
$50
Sobreponderar
TD Cowen
Comprar
$55
2026-10-01
TD Cowen
2026-10-01
Precio objetivo
$55
Comprar
Oppenheimer
Superar al mercado
$50
2026-09-23
Oppenheimer
2026-09-23
Precio objetivo
$50
Superar al mercado
Leerink
Superar al mercado
$45
2026-09-09
Leerink
2026-09-09
Precio objetivo
$45
Superar al mercado
UBS
Comprar
$48
2026-09-04
UBS
2026-09-04
Precio objetivo
$48
Comprar
Métricas de valoración
El PER previsto actual de Teva Pharmaceutical Industries Limited.. (TEVA) es 7.05, frente a su media de 5 años de 6.03.
Escenarios de precio de Alphio AI para TEVA
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con TEVA en cartera
Cronología de eventos
Noticias
1.010-12NewsfilterTeva Pharmaceuticals to Host R&D Day on November 11, 2026
9.010-09stocktwitsTeva Receives FDA Approval for New Schizophrenia Injection
2.010-09CNBCSpaceX Boosts Starlink Service, Impacting Telecom Stocks
- 2.010-09Newsfilter
Teva Launches WELTRUZA™ for Schizophrenia Treatment
6.010-01CNBCLatest Wall Street Rating Updates
Preguntas frecuentes sobre TEVA, respondidas por Alphio AI
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Teva Pharmaceutical is a good buy right now due to its recent FDA approval of Weltruza, which has the potential to significantly increase market share in the mental health sector. The current price is $41.50, and analysts have set a price target range between $50 and $55, indicating a potential upside of 20% to 32%. Additionally, the stock has shown strong momentum with a 1-year change of +113.70% and a 20-day change of +6.46%. However, the main risk is the recent insider selling, which has increased by 764.83%, suggesting potential concerns among insiders about the company's future performance.
26 analysts cover TEVA: 4 rate it Buy, 17 Hold and 5 Sell. The average price target is 35.71.
Comunidad
Más ↗
$TEVA | UBS Reaffirms Buy Rating on Teva with $48 Price Target, Citing Celiac R&D Progress and 2027 Catalyst Pipeline UBS remains positive on Teva, pointing to Celiac-related developments and a steady pipeline of catalysts through 2027 as key drivers for long-term growth.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.